Basel, 07 December 2017 Roche’s Hemlibra every four weeks controlled bleeds in phase III study in haemophilia A Less frequent administration of Hemlibra demonstrated clinically meaningful bleed control Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive interim results from the phase III HAVEN 4 study evaluating Hemlibra® (emicizumab) prophylaxis dosed once every four weeks... Read more
Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer First Phase III combination trial of a cancer immunotherapy to show improvement in progression-free survival as an initial treatment... Read more
Download PDF Read more
Basel, 20 November 2017 Roche’s Hemlibra significantly reduced bleeds in phase III study in haemophilia A HAVEN 3 study met primary endpoint and key secondary endpoints Intra-patient comparison demonstrated superiority of Hemlibra prophylaxis compared to prior factor VIII prophylaxis Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the phase III HAVEN 3... Read more
Basel, 20 November 2017 Roche’s Hemlibra significantly reduced bleeds in phase III study in haemophilia A HAVEN 3 study met primary endpoint and key secondary endpoints Intra-patient comparison demonstrated superiority of Hemlibra prophylaxis compared to prior factor VIII prophylaxis Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the phase III HAVEN 3... Read more
Basel, 20 November 2017 Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer Data will be submitted to health authorities globally, including the US Food and Drug Administration (FDA)... Read more
Basel, 20 November 2017 Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer Data will be submitted to health authorities globally, including the US Food and Drug Administration (FDA)... Read more
November 7, 2017 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, announced the opening of its new office in Japan and new London location today. The new Tokyo office, right in the heart of the city, is Unchained Labs’ 6th office worldwide.... Read more
Download PDF Read more
Key Discoveries in the Therapeutic Application of Cord Blood: Improvement of Motor Function in Children with Cerebral Palsy WALTHAM, Mass.–(BUSINESS WIRE)– Research published in Stem Cells Translational Medicine shows encouraging developments related to using a child’s own cord blood to treat childhood brain injury known as cerebral palsy (CP). The research from a Phase II... Read more